Primary Biliary Cirrhosis
- 22 September 2005
- journal article
- review article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 353 (12), 1261-1273
- https://doi.org/10.1056/nejmra043898
Abstract
Primary biliary cirrhosis, a slowly progressive autoimmune liver disease characterized by portal inflammation and an immune-mediated destruction of the intrahepatic bile ducts, leads to decreased bile secretion and the retention of toxic substances within the liver. This review considers new data concerning both the autoimmune responses involved and the treatment of primary biliary cirrhosis.Keywords
This publication has 92 references indexed in Scilit:
- A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: Ten-year resultsHepatology, 2004
- Quantitative and functional analysis of PDC-E2–specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosisJCI Insight, 2002
- The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosisHepatology, 2000
- Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trialJournal of Hepatology, 2000
- Incidence of cancer in primary biliary cirrhosis: The mayo experienceHepatology, 1999
- Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot studyJournal of Hepatology, 1994
- The canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosisHepatology, 1994
- The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosisJournal of Hepatology, 1993
- A controlled trial of prednisolone treatment in primary biliary cirrhosis: Three-year resultsJournal of Hepatology, 1992
- A Prospective Trial of Colchicine for Primary Biliary CirrhosisThe New England Journal of Medicine, 1986